Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 3
2004 4
2005 4
2006 7
2007 5
2008 9
2009 7
2010 4
2011 11
2012 12
2013 11
2014 17
2015 19
2016 17
2017 14
2018 10
2019 12
2020 9
2021 12
2022 10
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Olfactory dysfunction in LATY136F knock-in mice.
Kaneda M, Yagi-Nakanishi S, Ozaki F, Kondo S, Mizuguchi K, Kawano M, Malissen M, Malissen B, Yamada K, Yoshizaki T. Kaneda M, et al. Among authors: yoshizaki t. Auris Nasus Larynx. 2022 Apr;49(2):209-214. doi: 10.1016/j.anl.2021.07.009. Epub 2021 Aug 1. Auris Nasus Larynx. 2022. PMID: 34348847
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. Takahashi S, et al. Among authors: yoshizaki t. Int J Clin Oncol. 2022 Dec;27(12):1805-1817. doi: 10.1007/s10147-022-02233-6. Epub 2022 Oct 20. Int J Clin Oncol. 2022. PMID: 36264378 Free PMC article. Clinical Trial.
Reply to P. Kaul et al.
Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, Uemura H, Sugasawa M, Yoshizaki T, Homma A, Chikamatsu K, Suzuki M, Shiotani A, Matsuzuka T, Kohno N, Miyazaki M, Oze I, Matsuo K, Kosuda S, Yatabe Y. Hasegawa Y, et al. Among authors: yoshizaki t. J Clin Oncol. 2021 Nov 1;39(31):3518-3519. doi: 10.1200/JCO.21.01554. Epub 2021 Sep 10. J Clin Oncol. 2021. PMID: 34506232 No abstract available.
In-scalp incision technique for cochlear implantation.
Sugimoto H, Hatano M, Yoshizaki T. Sugimoto H, et al. Among authors: yoshizaki t. Clin Otolaryngol. 2021 Jan;46(1):101-105. doi: 10.1111/coa.13630. Epub 2020 Nov 3. Clin Otolaryngol. 2021. PMID: 32790042 No abstract available.
171 results